Copyright
©2011 Baishideng Publishing Group Co.
World J Hepatol. Jun 27, 2011; 3(6): 147-156
Published online Jun 27, 2011. doi: 10.4254/wjh.v3.i6.147
Published online Jun 27, 2011. doi: 10.4254/wjh.v3.i6.147
Age group | anti-HBs IgG level | Number of serum samplesTested | HBV-DNA by nestedMultiplex PCR n (%) | HBc antibodyIgG n (%) | HBe IgG antibodyn (%) |
Group I Children (2-<4 years) | Low | 27 | 0 | 0 | 0 |
Negative | 8 | 0 | 0 | 0 | |
High | 20 | 0 | 0 | 0 | |
Group II Children (4-13 years) | Low | 178 | 4 (2.5) | 2 (1.2) | 0 |
Negative | 53 | 14 (26.4) | 1 (1.9) | 1 (1.9) | |
High | 14 | 0 | 0 | 0 | |
Group III Adults (20-47 years) | Low | 32 | 2a (6.25) | 1 (3.1) | 1 (3.1) |
Negative | 21 | 2a (9.52) | 1 (4.8) | 1 (4.8) | |
High | 7 | 0 | 0 | 0 | |
Total | 360 | 22 (6.11) | 5 (1.38) | 3 (0.83) |
- Citation: Abushady EA, Gameel MM, Klena JD, Ahmed SF, Abdel-Wahab KS, Fahmy SM. HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt. World J Hepatol 2011; 3(6): 147-156
- URL: https://www.wjgnet.com/1948-5182/full/v3/i6/147.htm
- DOI: https://dx.doi.org/10.4254/wjh.v3.i6.147